Gosset Ownership
Private
Employees
~8
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Amber Ophthalmics General Information
Amber Ophthalmics’ lead candidate Nexagon (lufepirsen ophthalmic gel) has shown promising results in a Phase 2 trial for PCED, with 67% of treated patients achieving complete corneal epithelial recovery versus 27% on placebo. The ongoing NEXPEDE‑1 study is a randomized, double-masked, vehicle-controlled Phase 2/3 trial evaluating two concentrations of Nexagon for PCED. The company’s approach leverages an unmodified antisense oligonucleotide targeting connexin43 to restore ocular homeostasis and promote healing in rare anterior segment eye diseases.
Contact Information
Primary Industry
Biotech
Corporate Office
San Diego, California
United States
United States
Drug Pipeline
lufepirsen
Phase 2/3Key Partnerships
Amber Ophthalmics Funding
No funding data available
To view Amber Ophthalmics's complete valuation and funding history, request access »